SCHEMBL3723971

SCHEMBL3723971

NCc1cccc(-c2ccc(Cl)cc2)c1

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.69
PNMT P11086 1/20 0.61
AOC3 Q16853 2/20 0.55
MAOB P27338 3/20 0.53
HRH3 Q9Y5N1 1/20 0.50
CYP1A2 P05177 1/20 0.48
HTR2C P28335 1/20 0.47
MRGPRX4 Q96LA9 1/20 0.46
HSD17B3 P37058 1/20 0.46
CSNK2A1 P68400 2/20 0.46
FGFR1 P11362 1/20 0.46
FGFR2 P21802 1/20 0.46
FGFR3 P22607 1/20 0.46
SHMT1 P34896 1/20 0.46
SHMT2 P34897 1/20 0.46
ENPP2 Q13822 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL184282 0.98 TAAR1 (0.67) TAAR1PNMTAOC3MAOBHRH3
SCHEMBL3794460 0.87 TAAR1 (0.70) TAAR1PNMTMAOBHRH3FGFR1
SCHEMBL5471659 0.86 TAAR1 (0.78) TAAR1PNMTAOC3MAOBMRGPRX4
SCHEMBL28247640 0.85 TAAR1 (0.74) TAAR1PNMTAOC3HRH3CSNK2A1
SCHEMBL3791745 0.85 LOXL2 (0.60) TAAR1PNMTHRH3CSNK2A1FGFR1
SCHEMBL29400616 0.83 TAAR1 (0.70) TAAR1PNMTAOC3HRH3CSNK2A1
SCHEMBL43554 0.83 TAAR1 (0.70) TAAR1PNMTAOC3HRH3CSNK2A1
SCHEMBL2092888 0.83 HRH3 (0.74) TAAR1PNMTMAOBHRH3CYP1A2
SCHEMBL2690730 0.82 TAAR1 (1.00) TAAR1PNMTMAOBHRH3CSNK2A1
SCHEMBL3720966 0.82 LOXL2 (0.56) TAAR1PNMTMAOBHRH3FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8614201-B2 Heterocyclic amides as modulators of TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2013-12-24 US claimed
WO-2010141805-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2010-12-09 WO claimed
EP-2600874-B1 PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE AMGEN INC (US) 2015-03-04 EP disclosed
US-8716281-B2 Pyrimidine compounds that inhibit anaplastic lymphoma kinase AMGEN INC. (US) 2014-05-06 US disclosed
US-8716281-B2 Pyrimidine compounds that inhibit anaplastic lymphoma kinase AMGEN INC. (US) 2014-05-06 US disclosed
US-8614201-B2 Heterocyclic amides as modulators of TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2013-12-24 US disclosed
US-20130158019-A1 PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE AMGEN INC. (US) 2013-06-20 US disclosed
US-20130158019-A1 PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE AMGEN INC. (US) 2013-06-20 US disclosed
WO-2011143033-A1 PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE AMGEN INC. (US) 2011-11-17 WO disclosed
WO-2010141805-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158019-A1 PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE DCK, DTYMK, TYMS TAAR1 3557/4885PNMT 1657/4885AOC3 3294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.